Market Overview

Ascendiant Capital Initiates Cytori Therapeutics With Buy

Related CYTX
The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering
The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Ascendiant Capital initiated coverage on Cytori Therapeutics Inc (NASDAQ: CYTX) with a Buy rating.

The target price for Cytori Therapeutics is set to $1.25.

Cytori Therapeutics shares have dropped 69.00 percent over the past 52 weeks, while the S&P 500 index has surged 10.96 percent in the same period.

Cytori Therapeutics' shares climbed 2.69 percent to $0.730 in after-hours trading.

Latest Ratings for CYTX

Aug 2018Maxim GroupDowngradesBuyHold
Jul 2018Maxim GroupMaintainsBuyBuy
Mar 2018Maxim GroupMaintainsBuy

View More Analyst Ratings for CYTX
View the Latest Analyst Ratings

Posted-In: Ascendiant CapitalInitiation Analyst Ratings


Related Articles (CYTX)

View Comments and Join the Discussion!

Cantor Slaps 'Buy' Rating On Paratek Pharmaceuticals

Benzinga's Top Initiations